Inventor(s): ROBL et al. Appln. No.: 09/ 697,297 Series Code ↑ Serial No. ↑ Filed: October 27, 2000 Hon. Commissioner of Patents Washington, D.C. 20231 Sir: REPLY/AMENDMENT/LETT Group Art Unit 1632

J. T. Woitach Examiner:

Atty. Dkt. 0277165

Client Ref Appln. Title: Gynogenetic or Androgenetic Produciton

> of Pluripotent Cells and Cell Lines, And Use Thereof to Produce Differentiated

Cells and Tissues

Date: November 21, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim							
A. \(\sum \frac{NOT}{NOT}\) made B. \(\sum \subseteq \text{Withdrawn}\) See \(\frac{Required}{Separate} \) Paper (Pat-256)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
D. 23 made proviously							
2. Total Effective Claims	57	**minus	38	19	x \$18/\$9 =	+ \$171	103/203
3. Independent Claims	5	***minus	4	1	x \$84/\$42 =	+ \$42	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> application)					+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: November 28, 2002 NONE							
6. Petition is hereby made to extend the original due (1 mo) \$110/\$55 =						47 St. 48 (1)	115/215
date to cover the date this response is filed for which the (2 mos) \$400/\$200 = + \$0							116/216
requisite fee is attached (3 mos) \$920/\$460 =							117/217 118/218
		(4	mos)	\$1,440/\$720=			128/228
(5 mos) \$1,960/\$980=						44	120/220
7. Enter any previous extension fee g	- \$0		A Asset				
8. Extens						+ \$0	图 表示的
					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),						+ \$0	126
or if Rule 97(d) Request							126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)					x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$740/370	+ \$0	1179/1279
14. Petition fee for						+ \$0	
15. TOTAL FEE =						\$213	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".						PLEASE CHARGE	
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space. 18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.						OUR DEP. ACCT	
Our Deposit Account No. 03-3975)							
(Our Order No. 015837 0277165							

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

35,030

Pillsbury Winthrop LLP Intellectual Property Group

P.O. Box 10500 McLean, VA 22102 Tel: (703) 905-2000

By Atty: Robin L. Teskin

Reg. No.

(703) 905-2500

Sig:

Fax: Tel:

Atty/Sec: RLT/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments NOV $\,2\,$ 6 $\,2002$



ED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

James M. Robl et al.

Group Art Unit: 1632

Application Serial No. 09/697,297

Examiner: J.T.Woitach

Filed: October 27, 2000

Title: GYNOGENETIC OR ADROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL

LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES

REPLY PURSUANT TO 37 C.F.R. §1.111

RECEIVED

NOV 2 6 2002

Hon. Commissioner of Patents

Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Office Action [Non-Final Rejection] dated August 28, 2002, please amend the above-identified application as follows. Changes made are indicated in the attached Appendix.

In the Specification:

Please delete the paragraph beginning at page 1, line 5, and replace it with the following rewritten paragraph:

-- Cross Reference to Related Application

This application claims priority from U.S. Provisional Application Serial No. 60/161,987 filed on October 18, 1999.

Please delete the paragraph beginning at page 1, line 10, and replace it with the following rewritten paragraph:

DOE UNUELRA 00000119 033975